Loading...
Loading chart...




The current price of TRVN is 0 USD — it has increased 0 % in the last trading day.
Trevena, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company's product, OLINVYK (oliceridine) injection, is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. It is also engaged in three differentiated investigational drug candidates: TRV045, TRV250, and TRV734. TRV045 is a novel sphingosine-1-phosphate (S1P), receptor modulator that may offer a new, non-opioid approach to managing chronic pain, as well as treating epilepsy and seizure disorders. TRV250 is a G-protein biased delta-opioid receptor (DOR), agonist as a compound with a mechanism for the treatment of acute migraine. TRV734 is a new chemical entity (NCE) targeting the same mechanism of action at the mu-opioid receptor (MOR). TRV734 is used for the treatment of opioid use disorder.
Wall Street analysts forecast TRVN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRVN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Trevena Inc revenue for the last quarter amounts to 283.00K USD, increased 57.22 % YoY.
Trevena Inc. EPS for the last quarter amounts to -5.79 USD, increased 915.79 % YoY.
Trevena Inc (TRVN) has 23 emplpoyees as of February 02 2026.
Today TRVN has the market capitalization of 4.00M USD.